Health News Archive - April 15, 2009
Fast-food and soft drinks may boost children's risk of obesity, but they also make them happy, U.S. and Chinese researchers have found.
Routine screening for coronary artery disease in type 2 diabetes patients with no symptoms is unnecessary, U.S. researchers say.
NEW YORK, April 15 /PRNewswire-Asia/ -- AgFeed Industries, Inc. (FEED), one of the largest independent hog production and animal nutrient companies in China, today announced its entry into a genetics program arrangement with Hypor, a Hendrix Genetics Company.
BETHESDA, Md., April 15 /PRNewswire-FirstCall/ -- Micromet, Inc.
NEW YORK, April 15 /PRNewswire/ -- Centerview Partners announced that Alan Hartman, Richard Girling and Mark Robinson, three leading investment bankers specializing in the healthcare sector, have agreed to join the firm as partners to build its healthcare practice.
ORLANDO, FL, April 15 /PRNewswire/ - FormularyDecisions.com, an online platform for healthcare decision makers, is being officially introduced at AMCP's 21st Annual Meeting and Showcase by Dymaxium, Inc.
- Adjusted EPS Growth of 15.9 Percent (GAAP EPS Growth of 53.3 Percent) - - Confirms Double-Digit EPS Guidance Range for 2009 - - Increased 2009 Dividend by 11 Percent - ABBOTT PARK, Ill., April 15 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2009. Diluted earnings per share, excluding specified items, were $0.73, reflecting 15.9 percent growth, and $0.03 above the mid-point of Abbott's previous first-quarter guidance range.
QUEBEC CITY, April 15 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
ANDREW L. PECORA, MD, FACP, CPE TO JOIN NEOSTEM'S ADVISORY BOARD NEW YORK, April 15 /PRNewswire-FirstCall/ -- NeoStem, Inc.
REYKJAVIK, Iceland, April 15 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq:DCGN) today announced that in order to provide more time for the execution of strategic alternatives currently under consideration, it has elected to utilize a 30-day grace period for the scheduled April 15 interest payment on its outstanding 3.5% Senior Convertible Notes due 2011. About deCODE deCODE is a biopharmaceutical company developing drugs and DNA-based tests to improve the treatment, diagnosis and prevention of common diseases. Its therapeutic programs leverage the company's expertise in chemistry and structural biology, and deCODE's global leadership in human genetics has enabled it to identify key variations in the genome (SNPs) conferring increased risk of major public health challenges from cardiovascular disease to cancer.